Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events: A Pooled Analysis

Author： Brinton Eliot A.  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.11, Iss.3, 2011-06, pp. : 179-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline: A Pooled Analysis

By Tonstad Serena  

Drug Safety, Vol. 33, Iss. 4, 2010-04 ,pp. : 289-301

Adis International

Access to resources Recommend Favorite

Niacin extended-release/ lovastatin: combination therapy for lipid disorders

By Moon Yong SK   Kashyap Moti L  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 12, 2002-12 ,pp. : 1763-1771

Informa Healthcare

Access to resources Recommend Favorite

Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety

By Yadav Rahul   France Michael   Younis Naveed   Hama Salam   Ammori Basil J   Kwok See   Soran Handrean  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1345-1362

Informa Healthcare

Access to resources Recommend Favorite

Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials

By Bhadra Pritha   Petersel Danielle  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 17, 2010-12 ,pp. : 2805-2812

Informa Healthcare

Access to resources Recommend Favorite

Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia

By Thakkar Roopal B.  

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 2, 2009-01 ,pp. : 69-79

Adis International

Access to resources Recommend Favorite